tRNA biology in the omics era: Stress signalling dynamics and cancer progression. by Orioli, A.
Prospects & Overviews
tRNA biology in the omics era:
Stress signalling dynamics and
cancer progression
Andrea Orioli
Recent years have seen a burst in the number of studies
investigating tRNA biology. With the transition from a
gene-centred to a genome-centred perspective, tRNAs
and other RNA polymerase III transcripts surfaced as
active regulators of normal cell physiology and disease.
Novel strategies removing some of the hurdles that prevent
quantitative tRNA profiling revealed that the differential
exploitation of the tRNA pool critically affects the ability of
the cell to balance protein homeostasis during normal and
stress conditions. Furthermore, growing evidence indi-
cates that the adaptation of tRNA synthesis to cellular
dynamics can influence translation and mRNA stability to
drive carcinogenesis and other pathological disorders.
This review explores the contribution given by genomics,
transcriptomics and epitranscriptomics to the discovery of
emerging tRNA functions, and gives insights into some
of the technical challenges that still limit our understanding
of the RNA polymerase III transcriptional machinery.
Keywords:.epitranscriptomics; genomics; high-throughput; RNA
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Introduction
In 1958, Zamecnik and Hoagland discovered an RNAmolecule
capable of interacting withmicrosomes to effect the transfer of
amino acids to a growing peptide chain [1]. This RNA
intermediate, which would have later been named transfer
RNA (tRNA), redefined our understanding of the process
linking the genetic code to the protein sequence. The
discovery stimulated much interest in this novel class of
RNAs and was followed by 50 years of experiments that
contributed to their characterisation. The first tRNA sequence
was determined in 1965 by Holley and coworkers [2], who also
speculated about possible double strand arrangements and
proposed what would have been established as the common
cloverleaf structure of tRNAs. A breakthrough came in 1966,
when Francis Crick published ‘The Wobble Hypothesis’, [3] a
theory suggesting that the increased flexibility of base-pair
interactions between the first nucleotide of the tRNA
anticodon and the third nucleotide of the mRNA codon could
explain the degeneracy of the genetic code.
With tRNAs emerging as central adapters of translation, a
lot of interest developed around the mechanism of tRNA
transcription. Nevertheless, it was not until 1974 that RNA
polymerase III (Pol III) was recognised as the enzyme
responsible for the synthesis of tRNAs and 5S rRNAs [4],
based on the previous identification of three distinct forms of
RNA polymerases showing different salt requirements and a-
amanitin sensitivity [5, 6]. In the following years, a wealth of
experiments contributed in a piecemeal manner to our
understanding of Pol III transcriptional units. Biochemical
approaches revealed that Pol III was driven by a small number
of general transcription factors onto four different types of
promoters consisting of internal or external recognition
elements {reviewed in [7]} and terminated transcription at a
simple run of 4 thymidine residues on the coding DNA
strand [8]. In parallel, Pol III was found to provide the cell with
a few additional non-coding RNAs (ncRNAs), such as the 5S
rRNA, 7SK snRNA, U6 snRNA and others [9].
After many years of exciting discoveries, the main features
of the Pol III machinery had been decoded, revealing a
straightforward promoter organisation that contrasted with
the outstanding diversity of its Pol II counterpart. tRNAs were
considered to be in-excess molecules playing a marginal role
as adaptors in protein synthesis, but not active regulators of
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disease or metabolism. This notion changed in recent years,
when ‘omics’ technologies took the functional evaluation of
Pol III transcripts on a completely new dimension. This review
explores some of the recently emerged links between tRNA,
metabolism, and disease, with a focus on high-throughput
technologies that contributed to our current understanding of
tRNA biology (Table 1).
The evolving Pol III landscape: From
tRNA gene predictions to genomic
approaches
The introduction of computational algorithms to screen the
prokaryotic and eukaryotic genomes for conserved Pol III
elements marked the transition from model-gene to multi-
gene studies. Pol3scan successfully contributed to the
definition of the first tDNA repertoire in Saccharomyces
cerevisiae [10, 11], and was later implemented with secondary-
structure prediction and covariance model algorithms into
tRNAscan-SE [12], a fast-running program detecting putative
Pol III-transcribed genes with higher sensitivity and specific-
ity. tRNAscan-SE 2.0 outputs are currently deposited into
GtRNAdb 2.0 (gtrnadb.ucsc.edu), an online database which
includes over 367.000 tRNA gene predictions from 4.371
genomes and combines sequence information with non-
canonical features such as single nucleotide polymorphisms
and differential expression profiles [13].
ChIP-seq reveals Pol III binding dynamics in
multiple eukaryotes
While GtRNAdb 2.0 is an excellent platform to screen for
potential Pol III-transcribed tDNAs, it cannot be considered as
an alternative to the systematic identification of Pol III targets
by biochemical or genetic approaches. Genome-wide analyses
to identify in vivo Pol III binding sites were first carried out in
S. cerevisiae by the mean of chromatin immunoprecipitation
(ChIP). With this approach, DNA is cross-linked to Pol III or its
general transcription factors (GTFs), immunoprecipitated,
and subjected to microarray {ChIP-chip [14–16]} or next
generation sequencing {ChIP-seq [17]} analysis. These experi-
ments revealed Pol III binding at the vast majority of known
targets and an overall correlation with transcription as
determined by measurement of the corresponding RNA levels.
Surprisingly, only a small number of novel targets were
identified in the yeast genome [15], including eight Extra
TFIIIC (ETC) loci bound solely to TFIIIC at the exclusion of
other Pol III components. Six potential Pol III genes of
unknown function have recently been revealed in S. cerevisiae
(tRNA-like transcripts, TLT) by combining in vivo UV
crosslinking and analysis of cDNA (CRAC) [18] with immuno-
precipitation of the largest yeast Pol III subunit, Rpo31 [19].
Compared to lower eukaryotes, the functional annotationof
large and complexmammalian genomesmakesmapping of Pol
III readsamuchmorecomplicatedtask,whichwasonlyrecently
addressed in a multiplicity of ChIP-seq studies [20–31]. Thanks
to the gradual improvement in sequencing technologies and
downstream analysis platforms, Pol III and its general
transcription factors Brf1, Brf2, Bdp1 and TFIIIC were mapped
in both the mouse and human genomes. These analyses
revealedanunexpectedly lownumberofnewtargetsand turned
out to hit genomic regions corresponding mainly to known Pol
III loci {reviewed in [32]}. The leap in data volume from the
Illumina GAIIX to the300GB per flowcell of the HiSeq 2000/
2500 platform did not result in a burst of newly identified
targets, suggesting that further increasing thesequencingdepth
will not bring many new players into the game.
Among the non-canonical targets revealed by genome-wide
experiments, tDNA-like and SINEs were by far the most
abundant, the latter includingmostly B2 elements in themouse
and 7SL-derived Alu elements in humans [26, 27, 33]. A
comprehensive study comparing multiple human cell lines
identified a total of 162 high-confidence Alus bound by Pol III
factors [33], six ofwhichweredefinedas transcriptionally active
by an independent screening of ENCODERNA-seq datasets [34].
Only24Aluswerebound toPol III inmore thanonecell line [33],
supporting the hypothesis that Alu elements are controlled by
genetic or epigenetic features limiting their expression to a
certain state or tissue. As suggested by a recentwork combining
epigenetic studies with ChIP-bisulphite-sequencing (ChIP-BS-
Seq) tomap themethylation state of Pol III-bound Alus, it is the
methylation of H3K9, rather than DNA, that suppresses
accessibility of SINEs to the transcriptional machinery [35].
Among the novel Pol III loci, most interesting was the
identification in human cells [24] and mouse liver [26] of a
conserved antisense MIR (Mammalian Interspersed Repeat)
located in thefirst intronof thePOLR3Egene,whichencodes the
RPC5subunit ofPol III. Pol IIIoccupancyof theMIRmightcreate
a roadblock for Pol II transcription of the POLR3E gene and
provide the cell with a negative feedback loop that helps reduce
stochasticity in Pol III protein levels [26].
A large fraction of Pol III loci is silent
One of the most unexpected findings of ChIP-seq profiling in
human cells was the large number of annotated loci devoid of
Pol III [20, 22, 24, 30], a situation that strictly differs from the
uniform binding pattern observed in yeast [14–17]. In
immortalised human fibroblasts (IMR90hTert) grown under
multiple conditions, Pol III was absent from 32% of
annotated loci [30], suggesting that a large fraction of Pol
III genes is in a permanently repressed state. While cell-type
specific differences have been observed [20], these data
indicate a much narrower exploitation of the Pol III repertoire
than originally thought, possibly owing to genetic or
epigenetic features which differentiate Pol III-free genes from
their highly occupied counterparts [26, 30]. Interestingly, Pol
III-free genes present poor DNaseI hypersensitivity [36], which
reflects the poor accessibility of these chromatin regions.
ChIP-exo: A ChIP-based tool for high-resolution
mapping of Pol III components
ChIP-based approaches proved to be invaluable tools in
defining target sites on the genomic scale, but their spatial
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Table 1. Overview of high-throughput strategies applied to the study of Pol III transcription and tRNA modifications
Omics High-throughput strategy Refs.
Genomics ChIP-chip, ChIP-seq. Chromatin immunoprecipitation-based methods to map genome wide the
DNA binding site of a protein of interest or epigenetic mark.
[14–17, 20–31]
ChIP-exo. Similar to ChIP-seq, but adding l exonuclease digestion to achieve near single nucleotide
resolution.
[40]
DamIP-seq. High-throughput strategy to map protein-DNA transient interactions. The protein of
interest is fused with E.coli Dam, so that a permanent methyl mark is left on the DNA at target loci.
[30]
BioGRO. Biotin-based genomic run-on to map elongating RNA polymerases along the genome at
50bp resolution, starting from permeabilized cells.
[46]
NET-seqa. It generates native elongating transcripts profiles at single nucleotide resolution to
precisely reveal the strand-specific position of transcriptionally engaged RNA polymerases across the
genome.
[42]
CRAC. UV-crosslinking of nascent RNAs to RNA polymerases and analysis of cDNA to map genome-
wide binding sites of the elongating enzyme at 40–50bp resolution.
[19]
DNaseI-seq. It takes advantage of the hypersensitivity of cis regulatory elements to DNaseI digestion
to provide a quantitative measure of chromatin accessibility.
[36]
Bisulfite sequencing (BS-seq) and ChIP-BS-seq. A NGS strategy to identify 5-methylcitosine at
single base pair resolution in DNA (BS-seq) or protein-bound DNA (ChIP-BS-seq).
[35]
Transcriptomics tRNA microarray. tRNAs are hybridized to DNA probes mechanically spotted on a solid surface.
Limited to 8-nt resolution, unless the oligo template is chemically modified to allow detection of
single-base difference between tRNA isoacceptors (though it might not distinguish specific tRNAs
within the same group of isoacceptors). A high-throughput approach based on hybridization and
quantification of PCR-amplified tRNA-specific probes has been implemented.
[60, 72]
tRNA-seq. Standard two-step ligation protocol for the conversion of tRNA to cDNA. [87]
ARM-seq, DM-tRNA-seq. These techniques take advantage of the dealkylating ability of E. coli AlkB
to remove some of the roadblocks that interfere with cDNA synthesis. Improve the quantitative
analysis of tRNA expression in deep sequencing studies.
[85, 86]
tRNA-HydroSeq. tRNAs are partially hydrolyzed in alkaline conditions to facilitate deep sequencing
of complex secondary structures.
[82]
neusRNA-seq. Newly synthesized small RNAs (<400nt) are labelled with a nucleotide analog (5-
ethynyl uridine) to detect quantitative changes in the transcript population in response to various
stimuli.
[30]
cp-RNA-seq. It selectively amplifies RNAs containing a 20,30-cyclic phosphate at their 30-end, such as
U6 snRNA, 7SK snRNA, 50-tiRs and SHOTRNAs.
[95]
CLIP-seq (and variants HITS-CLIP, PAR-CLIP, iCLIP). A set of techniques based on crosslinking
and immunoprecipitation to study, transcriptome-wide, in vivo binding sites of a given protein on
RNA.
[93]
CLASH. A method to identify RNA-RNA interactions through UV-crosslinking and
immunoprecipitation of an interacting protein.
[92]
Epitranscriptomics tRNA microarray. Post-transcriptional modifications can be identified based on the different
hybridization capacity of modified versus unmodified tRNAs.
[84]
Standard small RNA-seq.With a bioinformatics approach, it can be used to study post-transcription
modifications at the precursor tRNAs level.
[80, 100, 101,
108]
ARM-seq. The property of certain chemical modifications to induce RT roadblocks can be exploited
to profile m1A, m3C and m1G modified ribonucleosides in nuclear and mitochondrial tRNAs.
[85]
c-seq, ICE-seq, RiboMeth-seq. High-throughput methods that use chemical reagents to convert
RT-silent modifications (pseudouridine for c-seq, inosine for ICE-seq and 20-O-methylation for
RiboMeth-seq) in RT roadblocks.
[102, 103, 106,
110, 111]
m6A-seq, m6A-miCLIP, m1A-ID-seqb.Modified RNAs are captured by immunoprecipitation with an
antibody that specifically recognizes m6A or m1A-containing ribonucleosides. m6A-miCLIP is a single
base resolution improvement over m6A-seq.
[116, 117, 120]
m5C profiling (RNA BS-seq, Aza-IP, miCLIP). Genome wide m5C maps can be obtained by RNA
bisulfite sequencing (RNA BS-seq), based on the same principle that m5C in RNA are insensitive to
bisulfite treatment. New methods (Aza-IP, miCLIP) enrich the RNA target of m5C-RNA
methyltransferases before directional cDNA sequencing.
[112–115]
Quantitative mass spectrometry (MS). MS approaches can detect the full range of modifications in
the global tRNA pool. Sequence mapping of modified nucleotides identified via MS is currently being
implemented.
[127, 128]
aPol III occupancy have not been specifically investigated in these works, but the authors detected reads mapping to Pol III
genes and suggest that NET-seq is amenable to the study of the three RNA polymerases.
bWhile not yet implemented to detect m1A in Pol III transcripts, the library preparation strategy is compatible with this
application.
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resolution is limited by the length of sheared chromatin
fragments. Nevertheless, local maxima in ChIP-seq data have
been successfully used to position BDP1 and BRF1, two
components of the general transcription factor (GTF) TFIIIB,
at 14–27 bp upstream of the TSS of tRNA genes [24],
consistent with previous footprint analyses [37, 38]. Higher
resolution maps have been obtained by ChIP-exo, an
evolution of the ChIP-seq procedure, where cross-linked
DNA immunoprecipitates are further degraded by a lambda
(l) exonuclease to achieve near single-base resolution [39].
This strategywasmostly applied to Pol II and its GTFs, but was
also used to reveal TBP binding 21 bp upstream of 386 tRNA
genes in human K562 cells [40] and has the potential to
precisely map the remaining core transcription factors of the
Pol III apparatus.
Tracking Pol III transcription: Pol III
occupancy as a proxy of pre-tRNAs
expression
With the publication of the first ChIP-seq datasets, Pol III
occupancy profiles have been established as a measure of
transcriptional activity. However, given the discrepancy
between RNA-seq and ChIP-seq profiles at numerous loci,
stalling of Pol III was proposed [23], based on similar
conclusions emerging from Pol II studies. Indeed, very
generalised pausing at protein-coding genes had been
suggested by genome-wide profiles revealing an uneven
distribution of Pol II, with signal accumulating near the
transcription start sites (TSSs) of certain gene bodies [41].
Promoter-proximal pausing of Pol II was later confirmed by
NET-seq (Native Elongation Transcript sequencing) and GRO-
seq (global run-on sequencing), and proposed as a mecha-
nism to allow rapid transcriptional activation in response to
environmental cues [42–44].
Pol III pausing was specifically investigated in human
cells with a novel method named newly-synthesised EU-
labelled small RNA-seq (neusRNA-seq); this strategy is based
on the selective enrichment of pulse-labelled small RNAs
generated under various conditions and provides a direct
evidence of the transcriptional activity of gene-bound Pol
III [30]. The good correlation between Pol III occupancy and
synthesis of EU-labelled pre-tRNAs that emerged from these
experiments strongly argues against the presence of
unproductive, arrested Pol III. The lack of evidence for Pol
III pausing suggests that, when compared to unprocessed
tRNAs emerging from a given chromatin state, ChIP-seq is
indeed a proxy of ongoing transcription, but not necessarily
a good predictor of mature tRNA levels. Since mature tRNAs
have half-lives up to 48–72 hours [45], their abundance could
reflect an earlier chromatin state that does not necessarily
correspond to the one captured at the moment of cross-
linking; this would explain the relatively poor correlation
between ChIP-seq and RNA-seq profiles that do not
discriminate mature from precursor tRNAs. However, these
experiments do not exclude transient Pol III pausing or slow
down during the transcription cycle, for example when
encountering TFIIIC or during termination. Interestingly,
biotin-based genomic run-on (BioGRO) in S. cerevisiae
revealed increased Pol III density downstream the TSS of
intron-containing tDNAs, a phenomenon that was not
observed at intron-less genes [46]. Pol III pausing might
take place on these genes, but the increased MNase
sensitivity of introns emerging from TFIIIC bootprints [47]
rather suggest the formation of an intron-mediated loop that
slows down elongation between the A-box and B-box. Thus,
although Pol III may have to pause transiently to travel from
beginning to end of its transcription units, there is presently
no evidence of stable pausing. If Pol II pausing has evolved to
facilitate a synchronous transcriptional response at complex
promoter structures [48], the comparatively simpler organi-
sation of Pol III promoters might have bypassed the need of
an additional regulatory layer.
tRNA expression dynamics in cell
physiology and disease
MAF1 drives gene-specific adaptation of Pol III
transcription to environmental cues
Eukaryotic cells have developed various sensing mechanisms
and signalling pathways to produce appropriate outcomes in
response to changing environments, such as an accurate
reorganisation of gene expression and translation dynam-
ics [49]. A central regulator of cell growth and proliferation is
the mTORC1 pathway, which integrates intracellular and
extracellular signals to control energy metabolism, lipogene-
sis and protein synthesis. To cope with the increased protein
demand that organisms face when transitioning towards
optimal growth conditions, mTORC1 stimulates Pol I and Pol
III activity to provide cells with sufficient amounts of rRNAs
and tRNAs [50]. mTORC1-dependent regulation of Pol III
transcription largely depends on MAF1, a direct mTOR
substrate conserved from yeast to humans [51–53]. Whereas
in yeast, Maf1 is an acute repressor affecting Pol III activity in
response to stress, in mammals a recent DamIP-seq study
mapping the transient interaction of MAF1 with target loci
identified the protein as a chronic repressor of Pol III
transcription [30]. DamIP-seq revealed that MAF1 localises at
certain Pol III genes during both favorable and stress
conditions, possibly to keep transcription in check when
nutrients are in excess; following nutrient deprivation, stress-
induced MAF1 dephosphorylation results in increased target-
ing of Pol III-bound genes, with a consequent decrease of the
transcriptional output. Thus, in mammalian cells MAF1
functions as a stress sensor to optimise cell survival in
response to environmental cues.
Considering that MAF1 directly binds Pol III to specifically
repress transcription initiation or re-initiation in vitro [54], it is
reasonable to expect an uniform gene response to changing
environments. While former ChIP-chip studies comparing Pol
III occupancy during different growth phases in S. cerevisiae
corroborated this hypothesis [16], more recent experiments
indicate that this is the exception rather than the rule. A deep
sequencing approach comparing Pol III occupancy and
transcription in human fibroblasts suggests a heterogeneous
A. Orioli Prospects & Overviews....
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and dynamic adaptation of Pol III transcription to various
stimuli [30]. When cells transition between optimal and sub-
optimal growth conditions such as absence of serum, two
classes of Pol III-transcribed genes showing different levels of
responsiveness are revealed. If a majority of the genes rapidly
adapts to the nutrient shift, a significant fraction, including
representatives of most tRNA isotypes and type III promoter
loci, remains actively transcribed under both favorable and
adverse conditions (Fig. 1). The mechanism driving this
differential response is still unclear, but this conclusion is
consistent with subsequent results obtained by high resolu-
tion CRAC in S. cerevisiae [19] and by ChIP-seq in mouse liver
(Nicolas Bonhoure, personal communication).
The observation of dynamically responsive tRNAs suggests
that phenotype modulation might be achieved through the
differential exploitation of certain tRNA genes. These genes
might have evolved in parallel with a subset of Pol III
housekeeping genes to ensure a constant supply of essential
RNAs and to avoid dramatic outcomes in environments that
reduce cell viability. Yet, many questions remain; for instance,
what are the factors responsible for upregulation or down-
regulation of specific tRNA genes? Expression of multiple
isoforms ormutations in TFIIIB, TFIIIC andPol III subunitsmay
modulate the preference or the strength of the interaction with
different tDNA isodecoders, explaining a shift in the tRNA
profile under certain pathological conditions [55]. However,
even within the same genetic background, Pol III transcription
shows heterogeneous adaptation to external stimuli [30],
suggesting that additional factors bypassing
the expectedly uniform response to MAF1-
mediated repression are in place. Could
higher-order chromosomal structures contrib-
ute to the modulation of tRNA levels? ETC
elements, identified in fission yeast [56] and
higher eukaryotes, function as insulators and
chromatin organiserby tetheringdistant sites to
the nuclear periphery [56, 57]. It is tempting to
speculate that, as suggested by microscopy
studies [58], Pol III genes aggregate in discrete
nuclear clusters for coordinated expression,
mirroring co-localisation of active mRNA genes
in Pol II ‘transcription factories’. [59]
Adaptive translation: A new trigger
of tumorigenesis
How do changes in tRNA expression influence
development anddisease?An increasing bodyof
work provides evidence that changes in tRNA
expression play a major role in the translational
control of specific mRNAs (Fig. 2), which are
often dysregulated in cancer and other patholog-
ical conditions. tRNA-specificmicroarrays showedelevated tRNA
levels innumerouscancer types, includingbreast tumorsamples,
cancerous breast cell lines and malignant plasma cells from
multiplemyeloma [60–62]. Although it is not clearwhether tRNA
overexpression is the cause or consequence of carcinogenesis,
recent work suggests that many of the mutations leading to
activation of oncogenes, or to loss of oncosuppressors, require
enhanced Pol III transcription to drive oncogenic transforma-
tion [63]. For example, c-Myc-driven anchorage independent
growthof IHHs cells and tumor formation inmice are suppressed
by tagetin inhibition of Pol III or partial knockdown of BRF1 [64,
65], providing evidence that Pol III overexpression may have
functional implications in tumorigenesis. These phenotypes are
mimicked by overexpression of the initiator methionine tRNA
(tRNAi
Met), which is responsible for the selection of the correct
start codon during translation initiation. In human breast
epithelial cells, overexpression of tRNAi
Met promotes increased
metabolic activity and proliferation [66] and, in a recent study, a
transgenic mouse carrying two extra copies of the tRNAi
Met gene
showed enhanced tumor growth and vascularisation [67]. The
latter was mainly due to tRNAi
Met-dependent secretion of type II
collagen by stromal fibroblasts, which in turn promoted
angiogenesis and was generally associated with the aggres-
siveness of primary ovarian tumors. This is reminiscent of studies
inDrosophilashowingthatelevatedtRNAi
Met levels inthefatbody
promote body growth due to enhanced systemic insulin
signalling [68]. While this theorise an endocrine relay for
tRNAi
Met-mediated growth triggering, overexpression of tRNAi
Met
canalsoleadtochangesintheglobaltRNAexpressionprofile[66],
suggesting that cell autonomous effects cannot be excluded.
Cellular fitness can also be affected by codon-tRNA
balance [69]. Gingold et al. [70] investigated this notion and
revealed that the levels of endogenous tRNAs adapt tomatch the
codon usage of mRNAs specifically expressed in differentiated
versus proliferating cells. As a result of codon adaptation to a
Figure 1. Pol III transcription adapts heterogeneously to stress
inputs. When cells are exposed to stress such as nutrient depriva-
tion, MAF1-targeting of transcriptionally engaged Pol III results in a
different transcriptional outcome. While a certain number of genes
do not respond to stress cues (stable tRNA genes) a consistent
number of genes (unstable tRNA genes) adapt its expression profile.
In principle, this tRNA pool could be differentially exploited to
modulate expression of mRNAs enriched in cognate codons.
....Prospects & Overviews A. Orioli
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specific tRNA pool, pro-tumorigenic mRNAs might be translated
more efficiently, though recent studies suggest that preferential
codon usage might simply be a strategy to optimise available
translational resources under certain cellular programs [71].
Specific phenotypic consequences can also be caused by the
alteration of single tRNA levels. For example, upregulation of
tRNAArgCCGandtRNAGluUUC inbreast cancercellsenhances the
translation efficiency of core target transcripts associated with
higher metastatic capacity and invasiveness [72]. In mice, rare
codon-bias influences the ability of KRAS to drive de novo
tumorigenesis [73, 74]. Moreover, loss of function of one of the
tRNAArg UCU isodecoders specifically expressed in the mouse
central nervous system is associated with increased ribosome
stalling and leads to neurodegeneration in GTPBP2-deficient
mice [75]. These studies support the idea that the large number of
isodecoder tRNA genes in complex organisms is not fully
redundant, but it is rather precisely exploited tomirror the codon
usage of selected transcripts expressed in certain programmes or
developmental states.
Overcoming the hurdles: Towards quantitative
profiling of tRNAs and tRNA-derived fragments
Custom-made microarrays have been for several years the
gold standard for the quantitative assessment of tRNAs in
biological samples. This approach has proven useful in
pioneering studies [76, 77], but it has been limited by its
poor dynamic range, resolution {though the more recent
use of chemically modified oligos allows detection of single-
base differences among tRNA isoacceptors [60]} and
scalability. The emergence of high-throughput technologies
has opened unforeseen possibilities for biologist studying
tRNA expression, offering increased sensitivity and the
possibility to analyse whole transcriptomes at a fraction of
the cost.
Despite numerous advantages, high-throughput technolo-
gieshavebeen intrinsicallyhamperedby theextensivesecondary
structure and abundant post-transcriptional modifications of
tRNAs that interferewith cDNA synthesis, a step required inmost
RNAsequencing librarypreparationprotocols. Dependingon the
dNTP concentrations and on the enzyme used, some of these
modifications (e.g. m1A, m1G, m3C,m22G, 2
0-O-methylation) slow
down reverse transcription or result in nucleotide misincorpora-
tion during sequencing library preparation [78–80]. Other
modifications, such as the 20-30-cyclic phosphate at the 30-end
of the humanU6 snRNA, can interfere with standard sequencing
methods based on ligation of RNA adapters [81]. tRNA-HydroSeq
overcomessomeof thesehurdlesviapartial alkalinehydrolysisof
purified tRNAs, which generates smaller fragments less likely of
harboring complex secondary structures and modifications that
interfere with deep RNA sequencing [82]. Themethod represents
a considerable improvement over standard tRNA-seq protocols,
but fragmentscarryingmodifications thathamperregular reverse
transcriptase (RT) activity might still be overlooked in the final
data set. An alternative approach relies on the selection of tRNAs
by hybridisation to specific probes, which are then used to
quantify the levels of cognate tRNAs by high-throughput
sequencing [72]. Although RNA hybridisation to DNA oligonu-
cleotides would still be hindered by modifications that interfere
with Watson–Crick base pairing {e.g. m1G, m1A, m22G, i
6A and
t6A [82–84]}, this method has the significant advantage of
bypassing the cDNA synthesis step. However, since it is based on
the splinted ligation of probe pairs specific for each family of
Figure 2. Mechanisms for tRNA-mediated translational control.
Translation efficiency of mRNAs can be modulated by global or
specific changes in the tRNA pool. Changes in tRNA expression are
often linked to cancer development, either via a global increase in
protein synthesis driven by tRNAi
Met upregulation, tRNA localization,
or adaptation of the tRNA pool to the codon usage of tumor-specific
mRNAs. The factors leading to differential tRNA expression are not
fully understood. tRNA processing and modification can further
regulate the translational output and play a role in stress adaptation
and pathological disorders.
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mature tRNA isoacceptors, it cannot discriminate individual
tRNAs within the same group of isoacceptors, nor identify
precursors or truncated transcripts.
To facilitate cDNA extension, two groups took an
enzymatic approach that significantly increased the number
and the length of reads mapping on tRNA genes. In ARM-seq,
the RNA is treated with Escherichia coli AlkB, a dealkylating
enzyme which efficiently demethylates m1A and m3C before
adapter binding and reverse transcription [85]. The deme-
thylating ability of this enzyme is further exploited in DM-
tRNA-seq, which combines wild-type AlkB with a D135S
mutant that efficiently targets m1G in addition to the regular
substrates [86]. The DM-tRNA-seq downstream library
preparation protocol is reminiscent of tRNA-seq [87], in that
it also has the capacity to capture truncated tRNA fragments
generated by premature RT termination at modified ribonu-
cleotides. However, compared to the two-step ligation
approach of tRNA-seq, DM-tRNA-seq bypasses the adapter
ligation step by using a thermostable group II intron reverse
transcriptase (TGIRT), which synthesises cDNA via a
template-switching mechanism and deals more easily with
highly structured tRNAs. On the other hand, owing to the
binding of adapters at both ends of the template, which
guarantees end-to-end sequencing, ARM-seq is the only
strategy that can discriminate tRNA fragments from full-
length mature tRNAs and pre-tRNAs. Thanks to this
peculiarity, ARM-seq identified a large number of m1A58-
modified pre-tRNAs, consistent with previous literature
showing extensive pre-tRNA modification [88].
Overall, tRNA-HydroSeq, ARM-seq and DM-tRNA-seq
represent powerful tools for researchers looking for more
efficient and sensitive ways to quantitatively monitor changes
in tRNA abundance and modifications. However, these
strategies might still overlook tRNAs harboring modifications
that interfere with seamless RT activity and each of them has
advantages or disadvantages in terms of discriminating full-
length from truncated tRNAs. This last consideration is
particularly relevant at the light of recent studies revealing
that tRNAs are not always the end product of Pol III
transcription. High-throughput sequencing and analysis of
small RNA libraries identified a novel class of ncRNAs that can
be broadly divided into three different subtypes based on their
primary cleavage location {reviewed in [89]}: tRNA-derived
fragments (tRFs), stress-induced tRNA halves (tiRs) and sex
hormone-dependent tRNA-derived RNAs (SHOTRNAs). Over
the past few years, a number of studies have implicated these
ncRNAs in distinct biological functions, such as tumor
suppression, oncogenic activity, regulation of gene expression
and protein synthesis [90–92]. For instance, CLIP-seq revealed
that specific tRFs can act as tumor suppressors by displacing
YBX1 from the 30UTR of oncogenic transcripts [93]. Also, 50-
tiRAla cooperates with the translational silencer YB-1 to inhibit
translation initiation by interfering with the cap-binding
complex eIF4F [94]. Given the emerging roles of these tRNA
fragments in normal cell physiology and human disease,
several computational and technical tools have been devel-
oped to differentiate them from small RNAs that arise from
degradation of longer transcripts. For example, cp-RNA-seq
was developed to selectively amplify 50-tiRs and 50-SHOTR-
NAs, which contain a characteristic 20,30-cyclic phosphate
generated by angiogenin-specific cleavage in the anticodon
loop of mature tRNAs [95].
Epitranscriptomics: The new frontier of
tRNA research?
tRNA modifications provide a new layer of
translational control
In eukaryotes, nuclear and mitochondrial-encoded tRNAs
carry a myriad of post-transcriptional chemical modifications
(http://modomics.genesilico.pl/; http://www.genesilico.pl/
rnapathwaysdb/). Some of these modifications are crucial
for correct tRNA folding and stability, while others can have a
dramatic effect on the decoding capacity of certain tRNAs
(Fig. 2). For instance, the tRNA modification N2,N2-dime-
thylguanosine-26 (m22G26) is differentially incorporated into
tRNAs due to a limiting amount of Trm1, so that in case of
tRNA overproduction a subset of tRNAs becomes m22G26
hypomodified in response to saturation of the modification
apparatus. Under conditions that decreases RNA polymerase
III activity in a maf1-dependent manner, such as serum
starvation or rapamycin treatment, a subset of tRNAs shows
increased m22G26 modification [82]. This phenomenon, which
is conserved from yeast to humans, has the effect to stabilise
correctly folded tRNAs, affecting the translational efficiency of
certain mRNA codons and potentially proteome composition.
The wobble nucleoside is well known for its ability to
decode multiple synonymous codons and modifications at
this position play a prominent role in the stress response
pathway and human diseases [45, 96, 97]. Trm9-catalysed
modifications at wobble U34 (mcm
5U34 and mcm
5s2U34) of
specific tRNAs regulate protein expression via codon-biased
translation of mRNAs enriched in cognate codons [98]. Loss of
U34 modifications slows down translation elongation and
elicits proteins aggregation, impairing the ability of cells to
maintain proteome integrity during stress [99].
High-throughput methods for detection of tRNA
modifications: Bioinformatics, chemical and
antibody-based strategies
Early methods for detection and quantitation of RNA
modifications were based on the differential hybridisation
capacity of modified versus unmodified RNAs. The principle
has been implemented in a microarray system and success-
fully employed to identify a number of tRNA modifications in
S. cerevisiae [84]. An alternative approach relies on the ability
of certain RNA modifications to induce misincorporation of
specific nucleotides when read by reverse transcriptase. Since
standard small RNA-seq library preparation protocols require
cDNA synthesis, with the right bioinformatics pipeline it is
possible to identify tRNA modifications that affect RT activity.
Based on the observation that specific nucleotides misincor-
poration occur at higher frequency than the standard error
rate, several authors identified known and novel tRNA post-
transcriptional modifications by comparing small RNA-seq
data sets with the underlying genomic sequence [80, 100, 101].
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A similar principle is applied to the identification of known
tRNAmodifications via tRNA-HydroSeq, which are detected as
misincorporations in the final data set and further validated
with genetic studies [82].
An advantage of the bioinformatics strategy is the
possibility to retrospectively validate, against existing RNA-
seq data sets, tRNA modification profiles obtained with other
tools or specific antibodies. Nevertheless, this approach is
limited to modifications that modulate RT activity. For RT-
silent modifications, such as pseudouridine (C), 20-O-
methylated nucleosides and others [78], specific chemical
treatments that add a bulky group to existing modifications
must be further applied. For example, the CMC reagent creates
with pseudouridine a stable adduct which is not hydrolysed at
basic pH. This property was implemented in C-seq for
transcriptome-wide mapping of pseudouridinylation, which
revealedC-residues in numerous transcripts including tRNAs
and the 7SK snRNA [102, 103].
20-O-methylation is another widespread modification
present in a plethora of RNAs. Defective 20-O-methylation in
the anticodon loop of the tRNAPhe isotype contributes to X-
linked intellectual disability [104] and 20-O-methylation of G18
in certain bacterial tRNAs can suppress activation of the
innate immune system [105]. RiboMeth-seq [106] takes
advantage of the differential alkaline-cleavage properties of
nucleotides adjacent to a 20-O-methylated site and provides a
promising avenue for detection of modified tRNAs from
limiting biological and clinical samples.
Inosine is a modified nucleoside produced by adenosine
deamination and detected as an A-to-G substitution in cDNA.
Based on the widespread differences between the RNA and
DNA sequences, standard RNA-seq experiments have been
used to identify numerous instances of A-to-I editing [107],
and revealed that inosine is incorporated both at the pre-tRNA
and mature tRNA level [108]. While this bioinformatics
approach is extremely powerful, great care must be taken
in the downstream analysis to discriminate true modifications
from potential false positives [109]. Additional biochemical
methods that more directly map inosine modifications in the
RNA strands should also be employed for further validation,
such as the recently proposed Inosine Chemical Erasing
followed by sequencing (ICE-seq). Studies using ICE-seq found
many instances of A-to-I editing in intronic Alu elements,
leading to the interesting conclusion that intronic editing
prevents aberrant exonisation of Alu sequences in the mature
mRNA [110, 111].
Among the most studied tRNA post-transcriptional modifi-
cation is 5-methylcytosine (m5C), which promotes protein
synthesis by protecting tRNAs from angiogenin-mediated
cleavage [112]. RNA bisulfite sequencing (RNA BS-seq), a
protocol based on the selective chemical deamination of
cytosine to uracil by bisulfite treatment, was the first NGS
method to provide a single nucleotide-resolutionmap ofm5C in
tRNAs and other Pol III transcripts [112, 113]. To overcome some
of the intrinsic RNA BS-seq caveats leading to false positives
detection, such as the presence of conversion-resistant
cytosines embedded in double stranded RNA stretches and
the inability to discriminatem5C from5-hydroxymethylcytosine
(5hmC), additional methods have been developed. 5-azacyti-
dine-mediated RNA immunoprecipitation {Aza-IP [114]} and
methylation iCLIP {miCLIP [112, 115]} selectively capture m5C-
modified RNAs thanks to the covalent bond formed with the
m5C RNA methyltransferases NSUN2 or DNMT2. Base-pair
resolution maps obtained with these two strategies, combined
with RNA BS-seq output, offer a high-fidelity profile of the
m5C epitranscriptome.
One of the main achievements in the field of RNA
modifications was the development of antibodies that bind
directly to modified nucleosides. For instance, low resolution
transcriptome-wide maps of N6-methyladenosine (m6A) were
obtained thanks to anti-m6A immunoprecipitation and deep-
sequencing (m6A-seq) of captured RNA fragments {reviewed
in [116]}. Recently, a single nucleotide resolution map of
m6A (m6A-miCLIP) was achieved, thanks to the ability of
certain antibodies to leave a unique signature mutation when
UV-crosslinked to the modified nucleoside [117]. While m6A is
absent from eukaryotic tRNAs, the presence of m6A within an
mRNA codon can slow down cognate tRNA decoding and
translation elongation [118], potentially perturbing accurate
protein folding [119].
A similar high-throughput methodology named m1A-ID-
seq recently enabled the detection of N1-methyladenosine
(m1A) across human mRNAs, revealing a dynamic adaptation
of the m1A methylome to serum starvation and oxidative
stress [120]. m1A occurs in both mRNAs and tRNAs and has
important implications in cell growth and protein synthesis.
m1A58 protects pre-tRNAi
Met from degradation by the nuclear
surveillance pathway [88, 121–123] and m1A-modified tRNAs
preferentially associate with polysomes to support transla-
tion via an ALKBH1-dependent mechanism [124]. Since m1A-
ID-seq was developed on a tRNA-depleted RNA fraction [120],
these data are currently of limited use to tRNA biologist.
However, the procedure could be easily adapted to include
tRNAs, providing a welcomed addition to techniques (ARM-
seq, DM-tRNA-seq, tRNA-HydroSeq and microarrays) that are
currently used to identify high-confidence m1A sites in
tRNAs.
Looking ahead: Mass spectrometry and direct
RNA sequencing for global profiling of the Pol III
epitranscriptome
Despite technological advancements, a truly comprehensive
strategy for precise quantification and characterisation of Pol
III-derived transcripts is still much needed. The golden
standard would be a method coupling direct RNA sequencing
with detection of post-transcriptional modifications, similar to
the SMRT (Single Molecule, Real-Time) sequencing technol-
ogy [125] which is routinely applied to DNA templates. Recent
advances have already proven the feasibility of direct RNA-seq
{[126], https://cws.nanoporetech.com/publications/}, which
hopefully will be made available on a commercial scale to the
broader scientific community. Besides NGS-based mapping,
mass spectrometry (MS) represents an alternative, reliable
technique to detect post-transcriptional modifications in any
given RNA. An MS-based approach was used to quantify the
majority of tRNA modifications in yeast [127], but the
technique has been traditionally limited by the inability to
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place a certainmodificationwithin its sequence context. Novel
approaches combining RNase digestion of tRNAs with liquid
chromatography tandem mass spectrometry (LC-MS/MS) for
sequence attribution [128] promise exciting developments in
the near future.
Conclusions and prospects
Inrecentyears,agrowingnumberofstudieshavefocusedonthe
implicationsof tRNAsandotherPol III transcripts indiseaseand
homeostasis. The discovery of differential tRNA expression, the
link between codon usage and the abundance of the
corresponding tRNA, and the impact of tRNA modifications
on translational control, were made possible by the comple-
mentation of traditional biochemical studies with omics
technologies. To understand the mechanisms linking Pol III
with phenotype modulation, I suggest that at least four
questions will need to be addressed in the near future; (i)
What specifies MAF1 recruitment on tRNA genes and how does
this contribute to the selective activation or repression of target
genes? (ii) Is translational control by specific tRNAs a
widespread mechanism that applies to more cancer types
and diseases? (iii) Is there a crosstalk between tRNAs, tiRs and
tRFs, and how does this impact on pathological outcomes? (iv)
What is the impact of reversible tRNA modifications on tRNA
expression, tRNA processing and translational efficiency? The
development of refined omics technologies will greatly help to
answer these outstanding questions.
Acknowledgments
I thank Nouria Hernandez, Nicolas Bonhoure and Francois
Mange for the thoughtful discussion and critical review of the
manuscript. This work was supported by the University of
Lausanne and the Swiss National Science Foundation (SNSF)
grants CRSI33_125230 and 31003A_132958.
The author has declared no conflict of interest.
References
1. Hoagland MB, Stephenson ML, Scott JF, Hecht LI, et al. 1958.
A soluble ribonucleic acid intermediate in protein synthesis. J Biol Chem
231: 241–57.
2. Holley RW. 1965. Structure of an alanine transfer ribonucleic acid.
JAMA 194: 868.
3. Crick FH. 1966. Codon-anticodon pairing: the wobble hypothesis. JMol
Biol 19: 548–55.
4. Weinmann R, Roeder RG. 1974. Role of DNA-dependent RNA
polymerase 3 in the transcription of the tRNA and 5S RNA genes.
Proc Natl Acad Sci USA 71: 1790–4.
5. Roeder RG, Rutter WJ. 1969. Multiple Forms of DNA-dependent RNA
polymerase in eukaryotic organisms. Nature 224: 234–7.
6. Kedinger C, Gniazdowski M, Mandel JL, Gissinger F, et al. 1970. a-
Amanitin: a specific inhibitor of one of two DNA-dependent RNA
polymerase activities from calf thymus. Biochem Biophys Res Commun
38: 165–71.
7. Orioli A, Pascali C, Pagano A, Teichmann M, et al. 2012. RNA
polymerase III transcription control elements: themes and variations.
Gene 493: 185–94.
8. Bogenhagen DF, Brown DD. 1981. Nucleotide sequences in Xenopus
5S DNA required for transcription termination. Cell 24: 261–70.
9. White RJ. 2011. Transcription by RNA polymerase III: more complex
than we thought. Nat Rev Genet 12: 459–63.
10. Pavesi A, Conterio F, Bolchi A, Dieci G, et al. 1994. Identification of
new eukaryotic tRNA genes in genomic DNA databases by a multistep
weight matrix analysis of transcriptional control regions. Nucleic Acids
Res 22: 1247–56.
11. Percudani R, Pavesi A, Ottonello S. 1997. Transfer RNA gene
redundancy and translational selection in Saccharomyces cerevisiae.
J Mol Biol 268: 322–30.
12. Lowe TM, Eddy SR. 1997. TRNAscan-SE: a program for inproved
detection of transfer RNA genes in genomic sequence. Nucleic Acids
Res 25: 955–64.
13. Chan PP, Lowe TM. 2016. GtRNAdb 2.0: an expanded database of
transfer RNA genes identified in complete and draft genomes. Nucleic
Acids Res 44: D184–9.
14. Roberts DN, Stewart AJ, Huff JT, Cairns BR. 2003. The RNA
polymerase III transcriptome revealed by genome-wide localization and
activity-occupancy relationships. Proc Natl Acad Sci USA 100:
14695–700.
15. Moqtaderi Z, Struhl K. 2004. Genome-wide occupancy profile of the
RNA polymerase III machinery in Saccharomyces cerevisiae reveals loci
with incomplete transcription complexes. Mol Cell Biol 24: 4118–27.
16. Harismendy O, Gendrel C-G, Soularue P, Gidrol X, et al. 2003.
Genome-wide location of yeast RNA polymerase III transcription
machinery. EMBO J 22: 4738–47.
17. Kumar Y, Bhargava P. 2013. A unique nucleosome arrangement,
maintained actively by chromatin remodelers facilitates transcription of
yeast tRNA genes. BMC Genomics 14: 402.
18. Granneman S, Kudla G, Petfalski E, Tollervey D. 2009. Identification
of protein binding sites onU3 snoRNA and pre-rRNA byUV cross-linking
and high-throughput analysis of cDNAs. TL  106 Proc Natl Acad Sci
USA 106 VN-: 9613–8.
19. Turowski TW, Lesniewska E, Delan-Forino C, Sayou C, et al. 2016.
Global analysis of transcriptionally engaged yeast RNA polymerase III
reveals extended tRNA transcripts. Genome Res 26: 933–44.
20. Oler AJ, Alla RK, Roberts DN, Wong A, et al. 2010. Human RNA
polymerase III transcriptomes and relationships to Pol II promoter
chromatin and enhancer-binding factors. Nat Struct Mol Biol 17: 620–8.
21. Barski A, Chepelev I, Liko D, Cuddapah S, et al. 2010. Pol II and its
associated epigenetic marks are present at Pol III-transcribed
noncoding RNA genes. Nat Struct Mol Biol 17: 629–34.
22. Moqtaderi Z, Wang J, Raha D, White RJ, et al. 2010. Genomic binding
profiles of functionally distinct RNA polymerase III transcription
complexes in human cells. Nat Struct Mol Biol 17: 635–40.
23. Raha D, Wang Z, Moqtaderi Z, Wu L, et al. 2010. Close association of
RNA polymerase II and many transcription factors with Pol III genes.
Proc Natl Acad Sci USA 107: 3639–44.
24. Canella D, Praz V, Reina JH, Cousin P, et al. 2010. Defining the RNA
polymerase III transcriptome: genome-wide localization of the RNA
polymerase III transcription machinery in human cells. Genome Res 20:
710–21.
25. Kutter C, Brown GD, GonScalves A, Wilson MD, et al. 2011. Pol III
binding in six mammals shows conservation among amino acid isotypes
despite divergence among tRNA genes. Nat Genet 43: 948–55.
26. Canella D, Bernasconi D, Gilardi F, LeMartelot G, et al. 2012.
A multiplicity of factors contributes to selective RNA polymerase III
occupancy of a subset of RNA polymerase III genes in mouse liver.
Genome Res 22: 666–80.
27. Renaud M, Praz V, Vieu E, Florens L, et al. 2014. Gene duplication
and neofunctionalization: POLR3G and POLR3GL. Genome Res 24:
37–51.
28. Schmitt BM, Rudolph KLM, Karagianni P, Fonseca NA, et al. 2014.
High-resolution mapping of transcriptional dynamics across tissue
development reveals a stable mRNA-tRNA interface. Genome Res 24:
1797–807.
29. Carrire L, Graziani S, Alibert O, Ghavi-Helm Y, et al. 2012. Genomic
binding of Pol III transcription machinery and relationship with TFIIS
transcription factor distribution in mouse embryonic stem cells. Nucleic
Acids Res 40: 270–83.
30. Orioli A, Praz V, Lho^te P, Hernandez N. 2016. Human MAF1 targets and
represses activeRNApolymerase III genesbypreventing recruitment rather
than inducing long-term transcriptional arrest. Genome Res 26: 624–35.
31. Bonhoure N, Bounova G, Bernasconi D, Praz V, et al. 2014.
Quantifying ChIP-seq data: a spiking method providing an internal
reference for sample-to-sample normalization. Genome Res 24:
1157–68.
....Prospects & Overviews A. Orioli
1600158 (9 of 11)Bioessays 39, 3, 1600158, 2016 The Authors. BioEssays Published by WILEY Periodicals, Inc.
R
e
v
ie
w
e
s
s
a
y
s
32. Dieci G, Conti A, Pagano A, Carnevali D. 2013. Identification of RNA
polymerase III-transcribed genes in eukaryotic genomes. Biochim
Biophys Acta 1829: 296–305.
33. Oler AJ, Traina-Dorge S, Derbes RS, Canella D, et al. 2012. Alu
expression in human cell lines and their retrotranspositional potential.
Mob DNA 3: 11.
34. Conti A, Carnevali D, Bollati V, Fustinoni S, et al. 2015. Identification of
RNA polymerase III-transcribed Alu loci by computational screening of
RNA-Seq data. Nucleic Acids Res 43: 817–35.
35. Varshney D, Vavrova-Anderson J, Oler AJ, Cowling VH, et al. 2015.
SINE transcription by RNA polymerase III is suppressed by histone
methylation but not by DNA methylation. Nat Commun 6: 6569.
36. ThurmanRE,RynesE,HumbertR,VierstraJ, etal.2012.Theaccessible
chromatin landscape of the human genome. Nature 489: 75–82.
37. BartholomewB, Durkovich D, Kassavetis GA, Geiduschek EP. 1993.
Orientation and topography of RNA polymerase III in transcription
complexes. Mol. Cell. Biol 13: 942–52.
38. Kassavetis GA, Bardeleben C, Kumar A, Ramirez E, et al. 1997.
Domains of the Brf component of RNA polymerase III transcription
factor IIIB (TFIIIB): functions in assembly of TFIIIB-DNA complexes and
recruitment of RNA polymerase to the promoter. Mol Cell Biol 17:
5299–306.
39. Rhee HS, Pugh BF. 2011. Comprehensive genome-wide protein-DNA
interactions detected at single-nucleotide resolution. Cell 147: 1408–19.
40. Pugh BF, Venters BJ. 2016. Genomic organization of human
transcription initiation complexes. PLoS ONE 11: e0149339.
41. Guenther MG, Levine SS, Boyer LA, Jaenisch R, et al. 2007.
A chromatin landmark and transcription initiation at most promoters in
human cells. Cell 130: 77–88.
42. Mayer A, Di Iulio J, Maleri S, Eser U, et al. 2015. Native elongating
transcript sequencing reveals human transcriptional activity at nucleo-
tide resolution. Cell 161: 541–4.
43. Danko CG, Hah N, Luo X, Martins AL, et al. 2013. Signaling pathways
differentially affect RNA polymerase II initiation, pausing, and elongation
rate in cells. Mol Cell 50: 212–22.
44. Core LJ, Martins AL, Danko CG, Waters CT, et al. 2014. Analysis of
nascent RNA identifies a unified architecture of initiation regions at
mammalian promoters and enhancers. Nat Genet 46: 1311–20.
45. HuangH-Y, Hopper A. 2016.Multiple layers of stress-induced regulation
in tRNA biology. Life 6: 16.
46. Jordan-Pla A, Gupta I, de Miguel-Jimenez L, Steinmetz LM, et al.
2015. Chromatin-dependent regulation of RNA polymerases II and III
activity throughout the transcription cycle. Nucleic Acids Res 43:
787–802.
47. Nagarajavel V, Iben JR, Howard BH, Maraia RJ, et al. 2013. Global
“bootprinting” reveals the elastic architecture of the yeast TFIIIB-TFIIIC
transcription complex in vivo. Nucleic Acids Res 41: 8135–43.
48. Adelman K, Lis JT. 2012. Promoter-proximal pausing of RNA
polymerase II: emerging roles in metazoans. Nat Rev Genet 13: 720–31.
49. de Nadal E, Ammerer G, Posas F. 2011. Controlling gene expression in
response to stress. Nat Rev Genet 12: 833–45.
50. Laplante M, Sabatini DM. 2013. Regulation of mTORC1 and its impact
on gene expression at a glance. J Cell Sci 126: 1713–9.
51. Shor B,Wu J, ShakeyQ, Toral-Barza L, et al. 2010. Requirement of the
mTOR kinase for the regulation of Maf1 phosphorylation and control of
RNA polymerase III-dependent transcription in cancer cells. J Biol Chem
285: 15380–92.
52. Michels AA, Robitaille AM, Buczynski-Ruchonnet D, Hodroj W, et al.
2010. MTORC1 directly phosphorylates and regulates human MAF1.
Mol Cell Biol 30: 3749–57.
53. Boguta M, Graczyk D. 2011. RNA polymerase III under control:
repression and de-repression. Trends Biochem Sci 36: 451–6.
54. Vannini A, Ringel R, Kusser AG, Berninghausen O, et al. 2010.
Molecular basis of RNA polymerase III transcription repression by Maf1.
Cell 143: 59–70.
55. Arimbasseri AG, Maraia RJ. 2016. RNA polymerase III advances:
structural and tRNA functional views. Trends Biochem Sci 41:
546–59.
56. Noma K, Cam HP, Maraia RJ, Grewal SI. 2006. A role for TFIIIC
transcription factor complex in genome organization. Cell 125: 859–72.
57. Simms TA, Dugas SL, Gremillion JC, Ibos ME, et al. 2008. TFIIIC
binding sites function as both heterochromatin barriers and
chromatin insulators in Saccharomyces cerevisiae. Eukaryot Cell
7: 2078–86.
58. Pombo A, Jackson DA, Hollinshead M, Wang Z, et al. 1999. Regional
specialization in human nuclei: visualization of discrete sites of
transcription by RNA polymerase III. EMBO J 18: 2241–53.
59. Sutherland H, Bickmore WA. 2009. Transcription factories: gene
expression in unions? Nat Rev Genet 10: 457–66.
60. Pavon-EternodM, Gomes S, Geslain R, Dai Q, et al. 2009. TRNA over-
expression in breast cancer and functional consequences. Nucleic
Acids Res 37: 7268–80.
61. Mahlab S, Tuller T, Linial M. 2012. Conservation of the relative tRNA
composition in healthy and cancerous tissues. RNA 18: 640–52.
62. Zhou Y, Goodenbour JM, Godley LA, Wickrema A, et al. 2009. High
levels of tRNA abundance and alteration of tRNA charging by bortezomib
in multiple myeloma. Biochem Biophys Res Commun 385: 160–4.
63. Grewal SS. 2015. Why should cancer biologists care about tRNAs?
tRNA synthesis, mRNA translation and the control of growth. Biochim
Biophys Acta 1849: 898–907.
64. Shukla SK, Kumar V. 2012. Hepatitis B virus X protein and c-Myc
cooperate in the upregulation of ribosome biogenesis and in cellular
transformation. FEBS J 279: 3859–71.
65. Johnson SA, Dubeau L, Johnson DL. 2008. Enhanced RNA
polymerase III-dependent transcription is required for oncogenic
transformation. J Biol Chem 283: 19184–91.
66. Pavon-Eternod M, Gomes S, Rosner MR, Pan T. 2013. Over-
expression of initiator methionine tRNA leads to global reprogramming
of tRNA expression and increased proliferation in human epithelial cells.
RNA 19: 461–6.
67. Clarke CJ, Berg TJ, Birch J, Zanivan S, et al. 2016. The initiator
methionine tRNA drives secretion of type II collagen from stromal
fibroblasts to promote article the initiator methionine tRNA drives
secretion of type II collagen from stromal fibroblasts to promote tumor
growth and angiogenesis. Curr Biol 26: 755–65.
68. Rideout EJ, Marshall L, Grewal SS. 2012. Drosophila RNA polymerase
III repressor Maf1 controls body size and developmental timing by
modulating tRNAiMet synthesis and systemic insulin signaling.Proc Natl
Acad Sci USA 109: 1139–44.
69. QianW, Yang J, Pearson NM,Maclean C, et al. 2012. Balanced codon
usage optimizes eukaryotic translational efficiency. PLoS Genet 8:
e1002603.
70. Gingold H, Tehler D, Christoffersen NR, Nielsen MM, et al. 2014.
A dual program for translation regulation in cellular proliferation and
differentiation. Cell 158: 1281–92.
71. Rudolph KLM, Schmitt BM, Villar D, White RJ, et al. 2016. Codon-
driven translational efficiency is stable across diverse mammalian cell
states. PLoS Genet 12: e1006024.
72. Goodarzi H, Nguyen HCB, Zhang S, Dill BD, et al. 2016. Modulated
expression of specific tRNAs drives gene expression and cancer
progression. Cell 165: 1416–27.
73. Lampson BL, Pershing NLK, Prinz JA, Lacsina JR, et al. 2013. Rare
codons regulate KRas oncogenesis. Curr Biol 23: 70–5.
74. Pershing NLK, Lampson BL, Belsky JA, Kaltenbrun E, et al. 2015.
Rare codons capacitate Kras-driven de novo tumorigenesis. J Clin
Invest 125: 222–33.
75. Ishimura R, Nagy G, Dotu I, Zhou H, et al. 2014. RNA function.
Ribosome stalling induced by mutation of a CNS-specific tRNA causes
neurodegeneration. Science 345: 455–9.
76. Dittmar KA, Mobley EM, Radek AJ, Pan T. 2004. Exploring the
regulation of tRNA distribution on the genomic scale. J Mol Biol 337:
31–47.
77. Dittmar KA, Goodenbour JM, Pan T. 2006. Tissue-specific differences
in human transfer RNA expression. PLoS Genet 2: 2107–15.
78. Basturea GN. 2013. Research methods for detection and quantitation
of RNA modifications. Mater Methods 3: 1–0.
79. Behm-Ansmant I, Helm M, Motorin Y. 2011. Use of specific chemical
reagents for detection of modified nucleotides in RNA. J Nucleic Acids
2011: 408053.
80. Ryvkin P, Leung YY, Silverman IM, Childress M, et al. 2013. HAMR:
high-throughput annotation of modified ribonucleotides. RNA 19:
1684–92.
81. Lund E, Dahlberg J. 1992. Cyclic 20,30-phosphates and nontemplated
nucleotides at the 30 end of spliceosomal U6 small nuclear RNA’s.
Science (80-.) 255: 327–30.
82. Arimbasseri AG, Blewett NH, Iben JR, Lamichhane TN, et al. 2015.
RNA polymerase III output is functionally linked to tRNA dimethyl-G26
modification. PLoS Genet 11: 1–22.
83. Hou YM, Li Z, Gamper H. 2006. Isolation of a site-specifically
modified RNA from an unmodified transcript. Nucleic Acids Res 34:
1–6.
84. Hiley SL, Jackman J, Babak T, Trochesset M, et al. 2005. Detection
and discovery of RNA modifications using microarrays. Nucleic Acids
Res 33: e2.
A. Orioli Prospects & Overviews....
1600158 (10 of 11) Bioessays 39, 3, 1600158, 2016 The Authors. BioEssays Published by WILEY Periodicals, Inc.
R
e
v
ie
w
e
s
s
a
y
s
85. Cozen AE, Quartley E, Holmes AD, Hrabeta-Robinson E, et al. 2015.
ARM-seq: AlkB-facilitated RNA methylation sequencing reveals a
complex landscapeofmodified tRNAfragments.NatMethods12:879–84.
86. Zheng G, Qin Y, Clark WC, Dai Q, et al. 2015. Efficient and quantitative
high-throughput tRNA sequencing. Nat Methods 12: 835–7.
87. Pang YLJ, Abo R, Levine SS, Dedon PC. 2014. Diverse cell stresses
induce unique patterns of tRNA up- and down-regulation: tRNA-seq for
quantifying changes in tRNA copy number. Nucleic Acids Res 42.
88. Phizicky EM, Hopper AK. 2010. TRNA biology charges to the front.
Genes Dev 24: 1832–60.
89. Kumar P, Kuscu C, Dutta A. 2016. Biogenesis and function of transfer
RNA-related fragments (tRFs). Trends Biochem Sci 41: 679–89.
90. Saikia M, Hatzoglou M. 2015. The many virtues of tRNA-derived
stress-induced RNAs (tiRNAs): discovering novel mechanisms of stress
response and effect on human health. J Biol Chem 290: 29761–8.
91. Anderson P, Ivanov P. 2014. TRNA fragments in human health and
disease. FEBS Lett 588: 4297–304.
92. Kumar P, Anaya J, Mudunuri SB, Dutta A. 2014. Meta-analysis of
tRNA derived RNA fragments reveals that they are evolutionarily
conserved and associate with AGO proteins to recognize specific RNA
targets. BMC Biol 12: 78.
93. Goodarzi H, Liu X, Nguyen HCB, Zhang S, et al. 2015. Endogenous
tRNA-derived fragments suppress breast cancer progression via YBX1
displacement. Cell 161: 790–802.
94. Ivanov P, Emara MM, Villen J, Gygi SP, et al. 2011. Angiogenin-
induced tRNA fragments inhibit translation initiation. Mol Cell 43:
613–23.
95. Honda S, Loher P, Shigematsu M, Palazzo JP, et al. 2015. Sex
hormone-dependent tRNA halves enhance cell proliferation in breast
and prostate cancers. Proc Natl Acad Sci USA 112: E3816–25.
96. Duechler M, Leszczynska G, Sochacka E, Nawrot B. 2016.
Nucleoside modifications in the regulation of gene expression: focus
on tRNA. Cell Mol Life Sci 73: 3075–95.
97. Torres AG, Batlle E, Ribas de Pouplana L. 2014. Role of tRNA
modifications in human diseases. Trends Mol Med 20: 306–14.
98. Deng W, Babu IR, Su D, Yin S, et al. 2015. Trm9-catalyzed tRNA
modifications regulate global protein expression by Codon-biased
translation. PLoS Genet 11: 1–23.
99. NedialkovaDD,LeidelSA.2015.Optimizationofcodontranslationratesvia
tRNA modifications maintains proteome integrity. Cell 161: 1606–18.
100. Iida K, Jin H, Zhu J-K. 2009. Bioinformatics analysis suggests base
modifications of tRNAs and miRNAs in Arabidopsis thaliana. BMC
Genomics 10: 155.
101. Ebhardt HA, Tsang HH, Dai DC, Liu Y, et al. 2009. Meta-analysis of
small RNA-sequencing errors reveals ubiquitous post-transcriptional
RNA modifications. Nucleic Acids Res 37: 2461–70.
102. Carlile TM, Rojas-Duran MF, Zinshteyn B, Shin H, et al. 2014.
Pseudouridine profiling reveals regulated mRNA pseudouridylation in
yeast and human cells. Nature 515: 143–6.
103. Schwartz S, Bernstein DA, Mumbach MR, Jovanovic M, et al. 2014.
Transcriptome-wide mapping reveals widespread dynamic-regulated
pseudouridylation of ncRNA and mRNA. Cell 159: 148–62.
104. Guy MP, Shaw M, Weiner CL, Hobson L, et al. 2015. Defects in tRNA
anticodon loop 20-O-methylation are implicated in nonsyndromic X-linked
intellectual disability due to mutations in FTSJ1. Hum. Mutat 36: 1176–87.
105. David R. 2012. Immune evasion: Gm18, a bacterial “invisibility cloak.
Nat Rev Micro 10: 238–9.
106. Marchand V, Blanloeil-Oillo F, Helm M, Motorin Y. 2016. Illumina-
basedRiboMethSeq approach for mapping of 20-O-Me residues in RNA.
Nucleic Acids Res 44: e135.
107. Li M, Wang IX, Li Y, Bruzel A, et al. 2011. Widespread RNA and DNA
sequence differences in the human transcriptome.Science (80-.)333: 53–8.
108. Torres AG, Pineyro D, Rodriguez-EscribaM, CamachoN, et al. 2015.
Inosine modifications in human tRNAs are incorporated at the precursor
tRNA level. Nucleic Acids Res 43: 5145–57.
109. Lin W, Piskol R, Tan MH, Li JB. 2012. Comment on “Widespread RNA
and DNA sequence differences in the human transcriptome.” Science
(80-.) 335: 1302.
110. Sakurai M, Yano T, Kawabata H, Ueda H, et al. 2010. Inosine
cyanoethylation identifies A-to-I RNA editing sites in the human
transcriptome. Nat Chem Biol 6: 733–40.
111. Sakurai M, Ueda H, Yano T, Okada S, et al. 2014. A biochemical
landscape of A-to-I RNA editing in the human brain transcriptome.
Genome Res 24: 522–34.
112. Blanco S, Dietmann S, Flores JV, Hussain S, et al. 2014. Aberrant
methylation of tRNAs links cellular stress to neuro-developmental
disorders. EMBO J 33: 1–20.
113. Schaefer M, Pollex T, Hanna K, Lyko F. 2009. RNA cytosine
methylation analysis by bisulfite sequencing. Nucleic Acids Res 37.
114. Khoddami V, Cairns BR. 2013. Identification of direct targets and
modified bases of RNA cytosine methyltransferases. Nat Biotechnol 31:
458–64.
115. Hussain S, Sajini AA, Blanco S, Dietmann S, et al. 2013. NSun2-
mediated cytosine-5 methylation of vault noncoding RNA determines its
processing into regulatory small RNAs. Cell Rep 4: 255–61.
116. Liu N, Pan T. 2016. N6-methyladenosine-encoded epitranscriptomics.
Nat Struct Mol Biol 23: 98–102.
117. Linder B, Grozhik AV, Olarerin-George AO, Meydan C, et al. 2015.
Single-nucleotide-resolution mapping of m6A and m6Am throughout
the transcriptome. Nat Methods 12: 767–72.
118. Choi J, Ieong K-W, Demirci H, Chen J, et al. 2016. N(6)-
methyladenosine in mRNA disrupts tRNA selection and translation-
elongation dynamics. Nat Struct Mol Biol 23: 110–5.
119. Kim SJ, Yoon JS, Shishido H, Yang Z, et al. 2015. Translational
tuning optimizes nascent protein folding in cells. Science (80-.) 348:
444–8.
120. Li X, Xiong X, Wang K, Wang L, et al. 2016. Transcriptome-wide
mapping reveals reversible and dynamic N1-methyladenosine methyl-
ome. Nat Chem Biol 12: 311–6.
121. Saikia M, Fu Y, Pavon-Eternod M, He C, et al. 2010. Genome-wide
analysis of N1-methyl-adenosinemodification in human tRNAs.RNA 16:
1317–27.
122. Anderson J, Phan L, Cuesta R, Carlson BA, et al. 1998. The essential
Gcd10p  Gcd14p nuclear complex is required for 1-methyladenosine
modification and maturation of initiator methionyl-tRNA. Genes Dev 3:
3650–62.
123. Kadaba S, Krueger A, Trice T, Krecic AM, et al. 2004. Nuclear
surveillance and degradation of hypomodified initiator tRNA Met in S.
cerevisiae. Genes Dev 18: 1227–40.
124. Liu F, Clark W, Luo G, Klungland A, et al. 2016. ALKBH1-mediated
tRNA demethylation regulates translation. Cell 167: 1–3.
125. FlusbergBA,Webster D, Lee J, Travers K, et al. 2010. Direct detection
of DNA methylation during single-molecule, real-time sequencing. Nat
Methods 7: 461–5.
126. Vilfan ID, Tsai Y-C, Clark TA, Wegener J, et al. 2013. Analysis of
RNA base modification and structural rearrangement by single-
molecule real-time detection of reverse transcription.
J Nanobiotechnology 11: 1.
127. Chan CTY, Dyavaiah M, DeMott MS, Taghizadeh K, et al. 2010.
A quantitative systems approach reveals dynamic control of tRNA
modifications during cellular stress. PLoS Genet 6: 1–9.
128. Ross R, Cao X, Yu N, Limbach PA. 2016. Sequence mapping of
transfer RNA chemical modifications by liquid chromatography tandem
mass spectrometry. Methods 107: 73–8.
....Prospects & Overviews A. Orioli
1600158 (11 of 11)Bioessays 39, 3, 1600158, 2016 The Authors. BioEssays Published by WILEY Periodicals, Inc.
R
e
v
ie
w
e
s
s
a
y
s
